We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

MRI Contrast Agent Enters Chinese Market

By HospiMedica staff writers
Posted on 02 Mar 2001
An MRI contrast agent that permits early detection of liver lesions has been approved for use in China by the Chinese State Drug Administration (SDA). More...
Around 240 million people in China are carriers of the hepatitis B virus, a leading cause of hepatoma, one of the top 10 cancers in China.

The contrast agent is fermoxide, called Feridex (or Endorem in Europe), was developed by Advanced Magnetics Inc. (Cambridge, MA, USA). The agent is being commercialized by Pharmagenesis Inc. (Palo Alto, CA, USA; www.pharmagenesis.net), a company engaged in developing anticancer therapies from purified extracts of plants that have been employed in traditional Chinese medicine for more than 4,000 years. Pharmagenesis has been providing Feridex to Chinese oncology and teaching hospitals.

"We are encouraged by the wide acceptance of Feridex by oncology doctors in China,” said Nicolas Druz, CEO and chairman of Pharmagenesis. "The launch of Feridex is an excellent preparation for our plans to import more oncology-related Western drugs to China.”


Related Links:
Pharmagenesis

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Patient Monitoring System
AlarmSense
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.